Rifampicin mono-resistant tuberculosis is not the same as multidrug-resistant tuberculosis: a descriptive study from Khayelitsha, South Africa
Preprint
Abstract
Rifampicin mono-resistant TB (RMR-TB) constitutes 38% of all rifampicin-resistant TB (RR-TB) in South Africa and is increasing. We aimed to compare RMR-TB with multidrug-resistant TB (MDR-TB) within a high TB, RR-TB and HIV burden setting. Patient-level clinical data and stored RR-TB isolates from 2008-2017 with available whole genome sequencing (WGS) data were used to describe risk factors associated with RMR-TB and to compare rifampicin-resistance (RR) conferring mutations between RMR-TB and MDR-TB. A subset of isolates with particular RR-conferring mutations were subjected to semi-quantitative rifampicin phenotypic drug susceptibility testing. Among 2,041 routinely diagnosed RR-TB patients, 463 (22.7%) had RMR-TB. HIV-positive individuals (adjusted Odds Ratio 1.4, 95% CI 1.1-1.9) and diagnosis between 2013-2017 versus 2008-2012 (aOR 1.3, 1.1-1.7) were associated with RMR-TB. Among 1,119 (54.8%) patients with available WGS data showing RR-TB, significant differences in the distribution of rpoB RR-conferring mutations between RMR-TB and MDR-TB isolates were observed. Mutations associated with high-level RR were more commonly found among MDR-TB isolates (811/889, 90.2% versus 162/230, 70.4% among RMR-TB, prpoB L430P mutation, conferring low-level RR, was identified in 32/230 (13.9%) RMR-TB versus 10/889 (1.1%) in MDR-TB (prpoB L430P mutation, 7 were phenotypically susceptible using the critical concentration of 0.5 µg/ml (range 0.125-1 µg/ml). The majority (215/230, 93.5%) of RMR-TB isolates showed susceptibility to all other TB drugs, highlighting the potential benefits of WGS for simplified treatment. These data suggest that the evolution of RMR-TB differs from MDR-TB with a potential contribution from HIV infection.Keywords
All Related Versions
- Published version: Antimicrobial Agents and Chemotherapy, 65 (11), e0036421.
This publication has 34 references indexed in Scilit:
- Whole Genome Sequencing Investigation of a Tuberculosis Outbreak in Port-au-Prince, Haiti Caused by a Strain with a “Low-Level” rpoB Mutation L511P – Insights into a Mechanism of Resistance EscalationPLOS ONE, 2015
- Rifampin Resistance Missed in Automated Liquid Culture System for Mycobacterium tuberculosis Isolates with Specific rpoB MutationsJournal of Clinical Microbiology, 2013
- Phenotypically occult multidrug-resistant Mycobacterium tuberculosis: dilemmas in diagnosis and treatmentJournal of Antimicrobial Chemotherapy, 2013
- Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test ResultsJournal of Clinical Microbiology, 2009
- The Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosisScience, 2006
- Safe Mycobacterium tuberculosis DNA Extraction Method That Does Not Compromise IntegrityJournal of Clinical Microbiology, 2006
- Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazidThe Lancet, 1999
- Risk Factors for Rifampin-monoresistant Tuberculosis: A Case-Control StudyAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Risk Factors for Rifampin Mono-resistant TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Rifampin‐Monoresistant Tuberculosis in New York City, 1993–1994Clinical Infectious Diseases, 1997